Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)
Silence Therapeutics (SLN) Receives a Buy From Morgan Stanley
Silence Therapeutics (SLN) Gets a Buy From Morgan Stanley
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating
Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Optimistic Buy Rating for Silence Therapeutics Based on Divesiran's Market Potential and Positive Clinical Outlook
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Intuitive Surgical (ISRG) and Silence Therapeutics (SLN)
Silence Therapeutics Analyst Ratings
Buy Rating Affirmed for Silence Therapeutics on Promising SiRNA Therapeutic Developments and Market Potential
Buy Rating on Silence Therapeutics: Positive Phase 2 Data and Potential for Blockbuster Revenues
Silence Therapeutics Analyst Ratings
Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $42 Price Target
Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Silence Therapeutics Analyst Ratings
Morgan Stanley Boosts Price Target on Silence Therapeutics to $45 From $29, Says Q4 Showed 'Meaningful Progress,' Keeps Overweight Rating
Silence Therapeutics Analyst Ratings
Bullish on Silence Therapeutics: Buy Rating Affirmed Amid Strong Phase 2 Results for Zerlasiran